|
Bridgehead
Consulting Assists Innovative Medical Device Company, Tyrell
Inc
March 2008
Bridgehead International
recently completed an independent due diligence study on Tyrell
Inc. as part of a fundraising programme.
Tyrell Inc. is a medical technology
company focused on the development of medical devices for
the treatment of skin lesions. Comprised of experts from both
the medical and consumer products industries, Tyrell develops
and market new, non-prescription medical devices based on
its proprietary ClearPoint™ Technology. The first of these
is Zeno™, for over-the-counter treatment of acne. Zeno™ was
given FDA clearance as a Class II medical device in June 2005.
A CE mark in Europe was granted in 2006 and the product is
also approved in Canada, Japan and a number of other Asian
markets. Further products based on the ClearPoint™ technology
are in development.
Paul Tufano, Chief Financial Officer of
Tyrell said:
"As an international medical device
company which has launched multiple devices spanning numerous
indications, we often have difficulty finding a consultancy
firm that has the depth of technical expertise and market
resources to assess the landscape with which we work.
"Our engagement of Bridgehead
has proven to be very valuable to the growth and operation
of our business. Their assessment of the competitive landscape,
our product strategy and the intellectual property environment
has driven many important changes to the way we have managed
the success of our business.
"We look forward to our
next engagement with Bridgehead and their very professional
team."
|
